Prostate:前列腺癌中胞外囊泡来源蛋白组织差异表达分析

2019-05-14 AlexYang MedSci原创

前列腺癌(PCa)和正常前列腺细胞系中的胞外囊泡(EVs)蛋白组分析能够促使人们发现PCa新的候选标记。这些蛋白包括了核输出蛋白XPO1(也称为CRM1)、EV相关的PDCD6IP蛋白(也称为ALIX)以及脂肪酸合成酶FASN。最近,有研究人员在详细鉴定过的前列腺癌群体中利用质谱分析和组织芯片(TMA)免疫组化技术调查了XPO1和PDCD6IP表达的差异,从而确定它们的诊断和预后值。研究包括了67

前列腺癌(PCa)和正常前列腺细胞系中的胞外囊泡(EVs)蛋白组分析能够促使人们发现PCa新的候选标记。这些蛋白包括了核输出蛋白XPO1(也称为CRM1)、EV相关的PDCD6IP蛋白(也称为ALIX)以及脂肪酸合成酶FASN。最近,有研究人员在详细鉴定过的前列腺癌群体中利用质谱分析和组织芯片(TMA)免疫组化技术调查了XPO1和PDCD6IP表达的差异,从而确定它们的诊断和预后值。

研究包括了67个组织样本,33个为正常临近前列腺样本(NAP),34个为前列腺癌样本(PCa)。研究人员利用无标签EVs定量鉴定PCa与NAP之间的差异表达基因。通过TMA,研究人员在481个根治性前列腺切除样本中评估了候选标记的预后。之后,研究人员在样本中对候选标记进行显色,并分析了与患者信息和临床病理结果的相关性。研究发现,在MS数据分析中,与NAP相比,XPO1在PCa中表达更高(P>0.0001)。PDCD6IP表达提高不显著(P=0.0501)。TMA组化分析中高XPO1显色与多变量模型中高格林森评分(P=0.002)和PCa相关的死亡有关(P=0.009)。

最后,研究人员指出,细胞质XPO1高表达与前列腺癌有关,增加了组织样本的临床价值。更多的是,作为一个细胞外囊泡蛋白,也许是一个新的相关液体生物标记。

原始出处:

Duijvesz D, Rodriguez-Blanco G, Hoogland AM et al. Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer. Prostate. 24 Apr 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1936630, encodeId=177919366304d, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Feb 16 20:07:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649201, encodeId=28c3164920125, content=<a href='/topic/show?id=591d48262d1' target=_blank style='color:#2F92EE;'>#差异表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48262, encryptionId=591d48262d1, topicName=差异表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7bc23772344, createdName=mfx807, createdTime=Sun Jun 16 18:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364485, encodeId=0308136448572, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599848, encodeId=f72c159984887, content=<a href='/topic/show?id=be324039e31' target=_blank style='color:#2F92EE;'>#囊泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40397, encryptionId=be324039e31, topicName=囊泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86bc18759177, createdName=charl1234573, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602155, encodeId=5f61160215569, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366253, encodeId=af51366253f1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed May 15 12:46:11 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040455, encodeId=d92b104045526, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 14 16:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1936630, encodeId=177919366304d, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Feb 16 20:07:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649201, encodeId=28c3164920125, content=<a href='/topic/show?id=591d48262d1' target=_blank style='color:#2F92EE;'>#差异表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48262, encryptionId=591d48262d1, topicName=差异表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7bc23772344, createdName=mfx807, createdTime=Sun Jun 16 18:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364485, encodeId=0308136448572, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599848, encodeId=f72c159984887, content=<a href='/topic/show?id=be324039e31' target=_blank style='color:#2F92EE;'>#囊泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40397, encryptionId=be324039e31, topicName=囊泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86bc18759177, createdName=charl1234573, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602155, encodeId=5f61160215569, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366253, encodeId=af51366253f1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed May 15 12:46:11 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040455, encodeId=d92b104045526, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 14 16:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1936630, encodeId=177919366304d, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Feb 16 20:07:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649201, encodeId=28c3164920125, content=<a href='/topic/show?id=591d48262d1' target=_blank style='color:#2F92EE;'>#差异表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48262, encryptionId=591d48262d1, topicName=差异表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7bc23772344, createdName=mfx807, createdTime=Sun Jun 16 18:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364485, encodeId=0308136448572, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599848, encodeId=f72c159984887, content=<a href='/topic/show?id=be324039e31' target=_blank style='color:#2F92EE;'>#囊泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40397, encryptionId=be324039e31, topicName=囊泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86bc18759177, createdName=charl1234573, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602155, encodeId=5f61160215569, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366253, encodeId=af51366253f1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed May 15 12:46:11 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040455, encodeId=d92b104045526, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 14 16:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-16 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1936630, encodeId=177919366304d, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Feb 16 20:07:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649201, encodeId=28c3164920125, content=<a href='/topic/show?id=591d48262d1' target=_blank style='color:#2F92EE;'>#差异表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48262, encryptionId=591d48262d1, topicName=差异表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7bc23772344, createdName=mfx807, createdTime=Sun Jun 16 18:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364485, encodeId=0308136448572, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599848, encodeId=f72c159984887, content=<a href='/topic/show?id=be324039e31' target=_blank style='color:#2F92EE;'>#囊泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40397, encryptionId=be324039e31, topicName=囊泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86bc18759177, createdName=charl1234573, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602155, encodeId=5f61160215569, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366253, encodeId=af51366253f1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed May 15 12:46:11 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040455, encodeId=d92b104045526, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 14 16:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1936630, encodeId=177919366304d, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Feb 16 20:07:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649201, encodeId=28c3164920125, content=<a href='/topic/show?id=591d48262d1' target=_blank style='color:#2F92EE;'>#差异表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48262, encryptionId=591d48262d1, topicName=差异表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7bc23772344, createdName=mfx807, createdTime=Sun Jun 16 18:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364485, encodeId=0308136448572, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599848, encodeId=f72c159984887, content=<a href='/topic/show?id=be324039e31' target=_blank style='color:#2F92EE;'>#囊泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40397, encryptionId=be324039e31, topicName=囊泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86bc18759177, createdName=charl1234573, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602155, encodeId=5f61160215569, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366253, encodeId=af51366253f1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed May 15 12:46:11 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040455, encodeId=d92b104045526, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 14 16:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-16 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1936630, encodeId=177919366304d, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Feb 16 20:07:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649201, encodeId=28c3164920125, content=<a href='/topic/show?id=591d48262d1' target=_blank style='color:#2F92EE;'>#差异表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48262, encryptionId=591d48262d1, topicName=差异表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7bc23772344, createdName=mfx807, createdTime=Sun Jun 16 18:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364485, encodeId=0308136448572, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599848, encodeId=f72c159984887, content=<a href='/topic/show?id=be324039e31' target=_blank style='color:#2F92EE;'>#囊泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40397, encryptionId=be324039e31, topicName=囊泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86bc18759177, createdName=charl1234573, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602155, encodeId=5f61160215569, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366253, encodeId=af51366253f1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed May 15 12:46:11 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040455, encodeId=d92b104045526, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 14 16:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-15 一个字-牛

    学习了谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1936630, encodeId=177919366304d, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Feb 16 20:07:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649201, encodeId=28c3164920125, content=<a href='/topic/show?id=591d48262d1' target=_blank style='color:#2F92EE;'>#差异表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48262, encryptionId=591d48262d1, topicName=差异表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7bc23772344, createdName=mfx807, createdTime=Sun Jun 16 18:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364485, encodeId=0308136448572, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599848, encodeId=f72c159984887, content=<a href='/topic/show?id=be324039e31' target=_blank style='color:#2F92EE;'>#囊泡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40397, encryptionId=be324039e31, topicName=囊泡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86bc18759177, createdName=charl1234573, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602155, encodeId=5f61160215569, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu May 16 04:07:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366253, encodeId=af51366253f1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed May 15 12:46:11 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040455, encodeId=d92b104045526, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 14 16:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-14 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Brit J Cancer:接受治疗的前列腺癌患者心血管事件风险

由此可见,生活方式、人体测量学指标或心血管危险因素并未解释接受姑息治疗的PCa患者的IS和HF风险。结果强调了在该患者组中平衡疾病管理和监测心血管健康的必要性。

Urology:泌尿专家实践结构与前列腺癌治疗花费

最近,有研究人员调查了泌尿专家实践结构对男性前列腺癌治疗花费的影响。研究人员假设了3个泌尿专家实践因素能够影响前列腺癌治疗的花费:泌尿科医师参与多专科组(MSG)、单独的专业泌尿外科组的实践规模和放射治疗强度(IMRT)所有权。研究人员鉴定了35929名新诊断为前列腺癌的男性,他们由6381名泌尿科专家进行诊治。研究发现,新诊断前列腺癌男性的医疗花费在MSGs组中显著更低($19,181 v. $

Mol Cancer Ther:Notch1活性缺失能够抑制前列腺癌的生长和转移

前列腺癌在男性相关死亡原因中仍旧占据主导地位。患有恶性疾病的患者基本都要经历激素阻断治疗。虽然起始的治疗非常有效,这些男性通常在未来2-3年会发展至致死的、去势抵抗性前列腺癌。去势抵抗性前列腺癌的标准治疗方法包括第二代抗雄激素治疗,但是只能延长患者寿命几个月。因此,加深对抵抗性产生机理的理解是必要的,最终目的就是要开发出恶性前列腺癌的新疗法。最近,有研究人员鉴定了Notch1作为前列腺癌的治疗靶标

Prostate Cancer P D:前列腺癌患者前列腺切除术后男性的死亡日期和死因调查

国家死亡指数(NDI)是一个集中式的数据库,包含了死亡证明相关信息,这些信息被健康和医疗调查人员用来参考确定人口动态统计情况。然而,该数据库经常包含错误的死因。由于NDI依赖于前列腺癌(PC)患者根治性前列腺切除(RP)相关研究的治疗结果数据,最近,有研究人员通过参考SEARCH数据库的死亡数据来确定NDI数据的可靠性。研究发现,在SEARCH中共有1312名男性死亡,然而,NDI却报道这些男性的

基因组研究证实,视网膜母细胞瘤基因突变导致前列腺癌死亡风险增加三倍

有史以来规模最大的晚期前列腺癌基因组学研究表明,在肿瘤中视网膜母细胞瘤基因突变的男性死亡的风险是没有该基因突变患者的三倍,标准治疗复发的可能性几乎是其七倍。